<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114265">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01849367</url>
  </required_header>
  <id_info>
    <org_study_id>HC13052</org_study_id>
    <nct_id>NCT01849367</nct_id>
  </id_info>
  <brief_title>Trial of Bilateral tDCS for Depression</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of New South Wales</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcranial direct current stimulation (tDCS) is a novel treatment approach for depression
      that has shown promising efficacy in four recent double-blind, randomized, sham-controlled
      trials (RCT) and a meta-analysis. Mood, cognitive test performance and biomarkers will be
      measured during the trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale for Depression (MADRS)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Active tDCS (1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active tDCS (2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eldith Neuroconn tDCS device</intervention_name>
    <arm_group_label>Active tDCS (1)</arm_group_label>
    <arm_group_label>Active tDCS (2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant meets criteria for a DSM-IV Major Depressive episode.

          2. MADRS score of 20 or more.

        Exclusion Criteria:

          1. Diagnosis (as defined by DSM-IV) of: any psychotic disorder (lifetime); eating
             disorder (current or within the past year); obsessive compulsive disorder (lifetime);
             post-traumatic stress disorder (current or within the past year); mental retardation.

          2. History of drug or alcohol abuse or dependence (as per DSM-IV criteria) within the
             last 3 months (except nicotine and caffeine).

          3. Inadequate response to ECT in the current episode of depression.

          4. Participant is on regular benzodiazepine medication which is not clinically
             appropriate to discontinue.

          5. Participant requires a rapid clinical response due to inanition, psychosis or high
             suicide risk.

          6. Neurological disorder or insult, e.g., recent stroke (CVA), which places participant
             at risk of seizure or neuronal damage with tDCS.

          7. Participant has metal in the cranium, skull defects, or skin lesions on scalp (cuts,
             abrasions, rash) at proposed electrode sites.

          8. Female participant who is pregnant, or of child-bearing age, sexually active and not
             using reliable contraception (urine test for pregnancy will be used).

          9. Participants who are not fluent in English will not be included in the trial for
             safety reasons.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Angelo Alonzo, PhD</last_name>
    <phone>61-2-93823720</phone>
    <email>a.alonzo@unsw.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donel Martin, PhD</last_name>
    <phone>61-2-93829261</phone>
    <email>donel.martin@unsw.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Black Dog Institute / University of New South Wales</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Alonzo, PhD</last_name>
      <phone>61-2-93823720</phone>
      <email>a.alonzo@unsw.edu.au</email>
    </contact>
    <investigator>
      <last_name>Colleen Loo, MBBS, FRANZCP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>May 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of New South Wales</investigator_affiliation>
    <investigator_full_name>Colleen Loo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
